CME Group (CME) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting reconvened following adjournment from May 14th, with key executives and the independent inspector of election present.
Shareholders were informed about the agenda, proxy materials, and rules of conduct available via the web portal.
Board and executive committee updates
Margaret Wright, Corporate Secretary, confirmed the presence of a quorum for most items except for item six and 8C.
Liz Cook will continue as a holdover Class B-3 director due to lack of quorum for her election.
Shareholder proposals
Proposals included amendments to eliminate certain Class B director election rights and the election of Class B-1 and B-2 directors.
Board recommended voting in favor of all presented proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from CME Group
- Q2 2026 revenue up 1% to $1.7B, with record market data and strong shareholder returns.CME
Q2 2026 - S&P 500 ESG Index rebranded as Scores and Screens, fueling growth in liquid ESG investment products.CME
Beyond ESG with Understanding the S&P 500 ESG Index Ecosystem Conference - Strong volumes, new product launches, and tech-driven change shape a dynamic market outlook.CME
Piper Sandler Global Exchange and Trading Conference 2024 - CFTC's Bitcoin perpetual approval sparks risk warnings amid new product launches and efficiency focus.CME
Piper Sandler Global Exchange and Fintech Conference - Class B Proposals seek to modernize board structure and offer payments to shareholders if approved.CME
Proxy filing - Record Q1 2026 revenue and net income driven by surging global trading volumes and innovation.CME
Q1 2026 - Board candidates stress governance, risk oversight, and shareholder advocacy for the 2026 meeting.CME
Proxy filing - Record revenue, earnings, and trading volumes, with strong innovation and capital returns.CME
Q4 2025 - Record Q2 revenue, net income, and trading volumes with broad-based growth and innovation.CME
Q2 2024